Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10. August 2020 16:01 ET
|
Abeona Therapeutics Inc.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
10. Juli 2020 07:30 ET
|
Abeona Therapeutics Inc.
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial...
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
08. Juli 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
18. Juni 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to...
Abeona Therapeutics leitet klinische Phase-3-Schlüsselstudie zur Beurteilung der Gentherapie EB-101 bei rezessiver dystropher Epidermolysis bullosa (RDEB) ein
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Die Studie ist für die Rekrutierung geöffnet und das Patientenscreening ist an der Stanford University angelaufen Das Unternehmen erwartet die Behandlung des ersten Patienten im ersten Quartal 2020 ...
Abeona Therapeutics lance un essai clinique pivot de phase 3 évaluant la thérapie génique EB-101 pour l'épidermolyse bulleuse dystrophique récessive
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier patient soit traité au cours du premier trimestre...
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
13. Januar 2020 09:00 ET
|
Abeona Therapeutics Inc.
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...